EU approves 3 new indications for GlaxoSmithKline Mepolizumab

GlaxoSmithKline (GSK) recently announced that the European Commission (EC) has approved the anti-inflammatory drug Nucala (mepolizumab, mepolizumab), which is a specific targeted inhibitor of interleukin 5 (IL-5) Monoclonal antibody for the treatment of 3 types of eosinophil-driven diseases: hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granuloma Vasculitis (EGPA)

In the European Union, Nucala has previously been approved as an add-on therapy for the treatment of severe eosinophilic asthma (SEA) patients 6 years of age and older

In the United States, Nucala has been approved to treat 4 indications: SEA, EPGA, HES, CRSwNP

Through targeted therapy to reduce eosinophils in the blood to normal levels, Nucala has shown therapeutic benefits in a series of eosinophil-driven diseases

The EU approval is based on data from a series of key Phase 3 studies that investigated the role of Nucala targeting IL-5 in the treatment of eosinophil-driven diseases.

Nucala's active pharmaceutical ingredient mepolizumab is a monoclonal antibody that specifically targets interleukin 5 (IL-5)

Based on the above-mentioned mechanism of action, Nucala is being developed for various diseases caused by inflammation caused by eosinophils

Nucala was approved at the end of 2015 and is the world's first biological therapy targeting IL-5

In July 2021, Nucala was approved in the United States and became the first anti-IL-5 therapy for the treatment of CRSwNP.

Note: The original text has been deleted

Original source: European Commission approves Nucala (mepolizumab) in three additional eosinophil-driven diseases